Mizoribine (MZ) is a potent immunosuppressant used in conjunction with other immunosuppressants to prevent and treat allograft rejection after organ transplantation. Although hyperuricemia is the most common side effect of MZ, there are no case reports of acute allograft renal failure associated with MZ. This report describes a patient who developed acute allograft renal failure and hyperuricemia during MZ treatment. Accordingly, MZ treatment was terminated, hemodialysis was initiated, and allopurinol was administered. Hemodialysis was necessary only once. The patient's condition improved with these treatments, and renal function recovered. Care should be taken during treatment with MZ to avoid latent renal dysfunction. Monitoring of serum uric acid levels was necessary. Moreover, it may be necessary to consider discontinuation of MZ and initiation of hemodialysis in cases of transient renal dysfunction. No prisoners were used and no organs from prisoners were used in the study.
第一作者单位：[1]Capital Med Univ, Dept Urol, Beijing Friendship Hosp, Beijing 100050, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Guo H. B..Acute Allograft Renal Failure With Marked Hyperuricemia Developing During Mizoribine Administration: A Case Report With Review of the Literature[J].TRANSPLANTATION PROCEEDINGS.2010,42(7):2804-2807.doi:10.1016/j.transproceed.2010.05.148.
APA：
Guo, H. B..(2010).Acute Allograft Renal Failure With Marked Hyperuricemia Developing During Mizoribine Administration: A Case Report With Review of the Literature.TRANSPLANTATION PROCEEDINGS,42,(7)
MLA：
Guo, H. B.."Acute Allograft Renal Failure With Marked Hyperuricemia Developing During Mizoribine Administration: A Case Report With Review of the Literature".TRANSPLANTATION PROCEEDINGS 42..7(2010):2804-2807
